Table 2.

Clinical and immunological features of SLE patients at entry into study (n=27)

Feature (n=27)	n (%) or median (IQR)*
Disease duration (years)	7.0 (3.5, 12)*
ANA-positive ever	27 (100)
ANA-positive at baseline visit	23 (85.2)
Elevated anti-dsDNA antibody†	7 (25.9)
Low C3†	3 (11.1)
Low C4†	10 (37.0)
Anti-cardiolipin antibody-positive†	8 (29.6)
Lupus anticoagulant present	1 (3.7)
Total BILAG-2004 ‘A’ scores (n)	27
Total BILAG-2004 ‘B’ scores (n)	16
Global BILAG-2004 score	14 (12, 22)*
SLEDAI-2K	6 (5,13)*
SLICC/ACR-DI	1 (1,2)*
Oral corticosteroids	24 (88.9)
Average daily corticosteroid dose (mg)	12.5 (10, 17.5)*
Current immunosuppressant use	12 (44.4)
Current antimalarial use	20 (74.1)

*Defined as positive/present at study entry unless stated.

†As per laboratory reference range.

ACR, American College of Rheumatology; ANA, antinuclear antibodies; BILAG, British Isles Lupus Assessment Group Disease Activity Index; DI, Damage Index; dsDNA, double-stranded DNA; SLE, systemic lupus erythematosus; SLEDAI-2K, SLE Disease Activity Index 2000; SLICC, Systemic Lupus International Collaborating Clinics.